Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: TRAUTSOLT
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.
Autorzy: Zychma Marcin J., Gumprecht Janusz, Strojek Krzysztof, Grzeszczak Władysław, Moczulski Dariusz, Trautsolt Wanda, Karasek Dariusz
Źródło: Med. Sci. Monitor 2002: 8 (7) s.CR512-CR515, tab., bibliogr. 15 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • endokrynologia
  • farmacja
  • genetyka

    Typ dokumentu:
  • tytuł obcojęzyczny
  • praca kliniczna
  • badanie porównawcze

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Background: The presence of a complex phenotype of type 2 diabetes results from impaired insulin secretion and action, whereas the emchanism of action of sulfonylurea derivatives, most commonly used int he treatment of type 2 diabetes, is based on their ability to directly inhibit the ATP-sensitive potassium channel (KATP), which leads to á-cell depolarization, subsequent influx of calcium and then insulin exocytosis. It has recently been demonstrated in healthy subjects that molecular variants of the gene encoding for the KATP subunit - sulfonylurea receptor gene (SUR1) are associated with a decreased response of insulin secretion to intravenous injection of tolbutamide, a suflonylurea derivative. In thid study we tested whether a molecular variant of the SUR1 gene, 16-3t, has a different distribution in type 2 diabetic patients with early failure of sulfonylurea therapy, compared to patients treatable iwth sufonylurea despite long diabetes duration. Material/Methods: The SUR1 polymorphism was genotyped in 68 type 2 diabetic patietns who required insulin treatment and had known diabetes duration ó 5 years, compared to 99 patients receiving oral agents (sulfonylurea alone or in combination with metformin or acarbose) with known diabetes duration of at least 15 years. Results: We obseverd no significant differences in SUR1 16-3t genotype distributions or allele frequencies between the two examined groups. Conclusion: Our study provides evidence against a major impact of the SUR1 c16-3t polymorphism on the long-term effectiveness of therapy with sulfonylurea derivatives in type 2 diabetic patients.

    stosując format: